Metaplastic Breast Carcinoma (MBC), Primary Squamous Cell Carcinoma Subtype in A 49-Year-Old Woman: A Case Report

Putu Erika Paskarani, Ni Gusti Ayu Agung Manik Yuniawaty Wetan, Ni Putu Sriwidyani, Sang Ayu Putu Yuliantini


Introduction: Metaplastic Breast Carcinoma (MBC) is quite a challenging case because metaplastic breast cancer is one of the rarest subtypes of invasive breast cancer. It is reported that MBC occurs only 0.2 to 1% throughout the world. The metaplastic changes can be squamous cells or other mesenchymal cell types. Clinically, MBC presents as a large palpable mass and may be associated with rapid growth. The size of MBC tends to be larger compared with other types of invasive breast cancer ranging from 1 to more than 10 cm. Although there are several main categories of MBC, some carcinoma can be difficult to classify due to their unusual histologic patterns. This case report study is to provide a clinicopathological overview and approach to MBC.

Case Presentation: We reported a 49-year-old woman who suffered from a breast mass that rapidly grew for less than one year. The microscopic findings showed squamous cell carcinoma. While molecular studies revealed triple negative results for hormone receptors although Human Epidermal Growth Factor Receptor 2 (HER2) overexpression was unusual (< 5%). Then, we confirmed with chromogen in situ hybridization (CISH) and there was no gen amplification for HER2. Microscopically, we found ductal carcinoma in situ and this finding supported breast origin.

Conclusions: Metaplastic carcinoma did not have any specific and distinctive signs clinically. Metaplastic carcinoma can be monophasic (with only a metaplastic component) or biphasic with two or more components. As treatment options, our patient received conventional chemotherapy. Metaplastic breast cancer is reported to have a lower response rate to conventional adjuvant chemotherapy and worse clinical outcome after chemotherapy than other forms of triple-negative breast cancer.


metaplastic breast cancer (MBC), squamous cell carcinoma subtype


Reis-Filho JS, Gobbi H, McCart Reed AE, et al. Metaplastic Carcinoma. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. World Health Organization Classification of Tumours, Breast tumours. 5th ed. France: International Agency for Research on Cancer; 2019. p.134-8.

Hammood ZD, Salih AM, Kakamad FH, et al. Metaplastic breast carcinoma with invasive and high grade ductal carcinoma in situ; a rare case with review literature. International Journal of Surgery Open. 2022:1-3.

Choi BB, Shu KS. Metaplastic carcinoma of the breast: multimodality imaging and histopathologic assessment. Acta Radiol. 2012;53(1):5.

Cooper R, Rajak R, Valentine K, and Bargava V. Diagnostic Histopathology. Elsevier; 2017.

Zein DE, Hughes M, Kumar S, et al. Metaplastic carcinoma of the breast is more aggressive than triple negative breast cancer; a study from single institution and review of literature. Clinical breast cancer. 2017;17(5):382-91.

Zhai J, Giannini G, Ewalt MD, et al. Molecular characterization of metaplastic breast carcinoma via next generation sequencing. Hum Pathol. 2018;86:85-92.

Kumar M, Nigam JS, Khana P, Arora A. Case report metaplastic carcinoma of the breast. International journal of surgery open. 2020;24:43-6.

Rakha EA, Tan PH, Varga Z, et al. Prognostic factors in metaplastic carcinoma of the breast: multi-institutional study. Br J Cancer. 2015;112(2):283-9.

Weigelt B, Charlotte KY, Shen R, et al. Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity. Mod Pathol. 2015;28(3):340-51.

Hicks DG amd Lester SC. Diagnostic Pathology Breast, 2nd Ed. Philadelphia: Elsevier;2016.

Full Text: PDF

DOI: 10.33371/ijoc.v16i4.932

Article Metrics

Abstract view : 92 times
PDF - 66 times


  • There are currently no refbacks.

Copyright (c) 2022 Indonesian Journal of Cancer